AAD
Author: Willhemenia Loremipsum Special session: Lorem ipsum dolor sit amet Category: Lorem ipsum View all results

Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

  • Presentation

Treating Atopic Dermatitis in Young Children: What's New, What's True?

Description

The discussion centers on the therapeutic approaches for treating atopic dermatitis (AD) in young children, emphasizing the prevalence of the condition and the challenges caregivers face in managing it. The speaker highlights the importance of addressing parental concerns regarding topical steroids, which are essential yet underutilized due to fears of side effects. A therapeutic ladder is outlined, with topical corticosteroids as the mainstay, supported by safety data that suggests their efficacy when used appropriately. Alternative treatments, such as calcineurin inhibitors and the newer topical medications like crisaborole, are also discussed, noting their specific age approvals and safety profiles. The talk covers systemic therapies, particularly dupilumab, which has revolutionized AD management in children under six, and highlights its favorable safety profile compared to older therapies with more severe side effects. The speaker encourages a proactive strategy in treating flares and using maintenance regimens to prevent recurrences, drawing parallels to asthma management. Future therapies, such as topical Janus kinase inhibitors, are anticipated to expand treatment options. The importance of appropriate dosing and understanding of the medications is emphasized throughout to alleviate anxiety in parents and enhance treatment adherence.

View more

Conclusions

  • Topical corticosteroids are essential for treating atopic dermatitis in young children.
  • Children may be prescribed lower potency topical corticosteroids due to fears of skin thinning, but safety data supports higher potency use when necessary.
  • There is significant reassurance regarding the safety of using topical corticosteroids, with low adverse event rates when used correctly.
  • Parents often have misconceptions about eczema treatments, leading to hesitation in using effective therapies.
  • Short-term, higher potency topical corticosteroids can clear severe eczema effectively without significant risk of systemic absorption or adverse effects.
  • Proper dosing and duration of therapy are critical in managing pediatric eczema effectively.
  • The introduction of biologic therapies like dupilumab has revolutionized the treatment landscape for severe atopic dermatitis in young children.
  • Emerging treatments, including topical JAK inhibitors and new non-steroidal options, show promising efficacy and safety for pediatric eczema.
  • Antimicrobial stewardship is essential as mupirocin resistance in Staphylococcus aureus is increasing in pediatric dermatitis populations.
  • Antonov NK, Garzon MC, Morel KD, Whittier S, Planet PJ, Lauren CT. High Prevalence of Mupirocin Resistance in Staphylococcus aureus Isolates from a Pediatric Population. Antimicrob Agents Chemother 2015;59:3350-6.
  • Eichenfield LF, Flohr C, Sidbury R, Siegfried E. Efficacy and Safety of Abrocitinib in Combination with Topical Therapy in Adolescents with Moderate-to-Severe Atopic Dermatitis: The JADE TEEN Randomized Clinical Trial. JAMA Dermatol 2021;157:1165-73.
  • Eichenfield, LF, Miller BH. Two randomized, double-blind, placebo-controlled studies of fluticasone propionate lotion 0.05% for the treatment of atopic dermatitis from 3 months of age. J Am Acad Dermatol 2006;54:715-7.
  • Friedlander SF, Hebert AA, Allen DB. Safety of fluticasone propionate cream 0.05% for the treatment of severe and extensive atopic dermatitis in children as young as 3 months. J Am Acad Dermatol 2002;46:387-93.
  • Paller AS, Flohr C, Cork M, Bewley A. Efficacy and Safety of Tralokinumab in Adolescents with Moderate to Severe Atopic Dermatitis: The Phase 3 ECZTRA 6 Randomized Clinical Trial. JAMA Dermatol 2023;159:596-605.
  • Paller AS, Siegfried EC, Simpson, EL. A phase 2, open-label study of single-dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy. J Eur Acad Dermatol.
  • Sigurgeirsson B, Boznanski A, Todd G et al. Safety and Efficacy of Pimecrolimus in Atopic Dermatitis: A 5-Year Randomized Trial. Pediatrics 2015;135:597-606.